2107
A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described.
 A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency: Subject; 17-year-old: Subject.Age; boy: Subject.Gender; alpha-1 antitrypsin deficiency: Subject.Disorder; syringotropic hypersensitivity reaction: Effect; 9 months of therapy with infliximab and leflunomide: Treatment; refractory psoriatic arthritis: Treatment.Disorder; infliximab: Treatment.Drug; leflunomide: Treatment.Drug; 9 months: Treatment.Duration; infliximab: Combination.Drug; leflunomide: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency: Subject; 17-year-old: Subject.Age; boy: Subject.Gender; alpha-1 antitrypsin deficiency: Subject.Disorder; syringotropic hypersensitivity reaction: Effect; 9 months of therapy with infliximab and leflunomide: Treatment; refractory psoriatic arthritis: Treatment.Disorder; infliximab: Treatment.Drug; leflunomide: Treatment.Drug; 9 months: Treatment.Duration; infliximab: Combination.Drug; leflunomide: Combination.Drug